Drug Trial Radar · NCT07443059
A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Apr 13, 2026
Primary completion
Dec 3, 2026
Study completion Mar 19, 2027
Sponsor
- Lead sponsor
- Beijing QL Biopharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-dose, open-label, parallel design phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of ZT002 Injection in participants with different degrees of renal insufficiency and matched participants with normal renal function.
Conditions
- Overweight , Obesity
Interventions
ZovaglutideDrug
Receive a single dose , SC
ZovaglutideDrug
Receive a single dose , SC
ZovaglutideDrug
Receive a single dose , SC
ZovaglutideDrug
Receive a single dose , SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration Versus Time Curve (AUC) of ZT002 From Time Zero to Tlast (AUC0-t).Time frame: Start of Treatment up to Day 50
- Maximum Concentration of ZT002 (Cmax)Time frame: Start of Treatment up to Day 50
- Area Under the Concentration Versus Time Curve (AUC) of ZT002 From Time Zero to Infinity (AUC0-∞)Time frame: Start of Treatment up to Day 50
- Time to maximum concentration (Tmax)Time frame: From baseline to Day 50
- Apparent terminal half-life (t1/2)Time frame: From baseline to Day 50
- Apparent clearance (CL/F)Time frame: From baseline to Day 50
- Incidence and severity of adverse eventsTime frame: Screening period up to Day 50
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
The First Affiliated Hospital Of Shandong First Medical Unversity
Jinan, Shandong, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.